Shiro Mizuno1, Harm J Bogaard2, Jose Gomez-Arroyo3, Aysar Alhussaini3, Donatas Kraskauskas3, Carlyne D Cool4, Norbert F Voelkel5. 1. Victoria Johnson Center for Obstructive Lung Diseases, Virginia Commonwealth University, Richmond, VA; Division of Respiratory Disease, Kanazawa Medical University, Ishikawa, Japan. 2. Victoria Johnson Center for Obstructive Lung Diseases, Virginia Commonwealth University, Richmond, VA; VU University Medical Center, Amsterdam, The Netherlands. 3. Victoria Johnson Center for Obstructive Lung Diseases, Virginia Commonwealth University, Richmond, VA. 4. Department of Pathology, University of Colorado Health Science Center, Lung Tissue Repository Consortium Repository, Aurora, CO. 5. Victoria Johnson Center for Obstructive Lung Diseases, Virginia Commonwealth University, Richmond, VA. Electronic address: nvoelkel@mcvh-vcu.edu.
Abstract
BACKGROUND: MicroRNAs (miRNAs) are small noncoding RNAs that silence target gene expression posttranscriptionally, and their impact on gene expression has been reported in various diseases. It has been reported that the expression of the hypoxia-inducible factor-1α (HIF-1α) is reduced and that of p53 is increased in lungs from patients with COPD. However, the role of miRNAs associated with these genes in lungs from patients with COPD is unknown. METHODS: Lung tissue samples from 55 patients were included in this study. Total RNA, miRNA, and protein were extracted from lung tissues and used for reverse transcriptase polymerase chain reaction and Western blot analysis. Cell culture experiments were performed using cultured human pulmonary microvascular endothelial cells (HPMVECs). RESULTS: miR-34a and miR-199a-5p expressions were increased, and the phosphorylation of AKT was decreased in the lung tissue samples of patients with COPD. The miR-199a-5p expression was correlated with HIF-1α protein expression in the lungs of patients with COPD. Transfection of HPMVECs with the miR-199a-5p precursor gene decreased HIF-1α protein expression, and transfection with the miR-34a precursor gene increased miR-199a-5p expression. CONCLUSIONS: These data suggest that miR-34a and miR-199a-5p contribute to the pathogenesis of COPD, and these miRNAs may also affect the HIF-1α-dependent lung structure maintenance program.
BACKGROUND: MicroRNAs (miRNAs) are small noncoding RNAs that silence target gene expression posttranscriptionally, and their impact on gene expression has been reported in various diseases. It has been reported that the expression of the hypoxia-inducible factor-1α (HIF-1α) is reduced and that of p53 is increased in lungs from patients with COPD. However, the role of miRNAs associated with these genes in lungs from patients with COPD is unknown. METHODS: Lung tissue samples from 55 patients were included in this study. Total RNA, miRNA, and protein were extracted from lung tissues and used for reverse transcriptase polymerase chain reaction and Western blot analysis. Cell culture experiments were performed using cultured human pulmonary microvascular endothelial cells (HPMVECs). RESULTS:miR-34a and miR-199a-5p expressions were increased, and the phosphorylation of AKT was decreased in the lung tissue samples of patients with COPD. The miR-199a-5p expression was correlated with HIF-1α protein expression in the lungs of patients with COPD. Transfection of HPMVECs with the miR-199a-5p precursor gene decreased HIF-1α protein expression, and transfection with the miR-34a precursor gene increased miR-199a-5p expression. CONCLUSIONS: These data suggest that miR-34a and miR-199a-5p contribute to the pathogenesis of COPD, and these miRNAs may also affect the HIF-1α-dependent lung structure maintenance program.
Authors: Geert R Van Pottelberge; Pieter Mestdagh; Ken R Bracke; Olivier Thas; Yannick M T A van Durme; Guy F Joos; Jo Vandesompele; Guy G Brusselle Journal: Am J Respir Crit Care Med Date: 2010-10-29 Impact factor: 21.405
Authors: Alberto Izzotti; Patrizia Larghero; Roumen Balansky; Ulrich Pfeffer; Vernon E Steele; Silvio De Flora Journal: Mutat Res Date: 2010-10-23 Impact factor: 2.433
Authors: Y Kasahara; R M Tuder; L Taraseviciene-Stewart; T D Le Cras; S Abman; P K Hirth; J Waltenberger; N F Voelkel Journal: J Clin Invest Date: 2000-12 Impact factor: 14.808
Authors: M Yasuo; S Mizuno; D Kraskauskas; H J Bogaard; R Natarajan; C D Cool; M Zamora; N F Voelkel Journal: Eur Respir J Date: 2010-06-18 Impact factor: 16.671
Authors: Dominador J Manalo; Ashley Rowan; Tera Lavoie; Lakshmi Natarajan; Brian D Kelly; Shui Q Ye; Joe G N Garcia; Gregg L Semenza Journal: Blood Date: 2004-09-16 Impact factor: 22.113
Authors: A Giatromanolaki; M I Koukourakis; E Sivridis; H Turley; K Talks; F Pezzella; K C Gatter; A L Harris Journal: Br J Cancer Date: 2001-09-14 Impact factor: 7.640
Authors: W M Chatila; G J Criner; W W Hancock; T Akimova; B Moldover; J-K Chang; W Cornwell; M Santerre; T J Rogers Journal: Clin Exp Immunol Date: 2014-07 Impact factor: 4.330